Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Starlite/ChEMBL | References |
Homo sapiens | integrin, beta 5 | Starlite/ChEMBL | References |
Homo sapiens | integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Starlite/ChEMBL | References |
Homo sapiens | integrin, alpha V | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | integrin alpha ps | integrin, alpha V | 1002 aa | 908 aa | 22.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0382 | 0.2226 | 0.2226 |
Schistosoma mansoni | hypothetical protein | 0.1006 | 1 | 1 |
Loa Loa (eye worm) | multisynthetase complex auxiliary component p43 | 0.0385 | 0.2255 | 0.2255 |
Brugia malayi | Integrin beta pat-3 precursor | 0.0817 | 0.7654 | 0.7409 |
Schistosoma mansoni | methionine-tRNA synthetase | 0.0382 | 0.2226 | 0.0203 |
Loa Loa (eye worm) | hypothetical protein | 0.0279 | 0.0943 | 0.0943 |
Echinococcus multilocularis | indoleamine 2,3 dioxygenase 2 | 0.1006 | 1 | 1 |
Echinococcus granulosus | methionyl tRNA synthetase cytoplasmic | 0.0382 | 0.2226 | 0.1372 |
Schistosoma mansoni | integrin beta subunit | 0.0475 | 0.3387 | 0.1667 |
Schistosoma mansoni | hypothetical protein | 0.1006 | 1 | 1 |
Loa Loa (eye worm) | integrin beta-2 | 0.0817 | 0.7654 | 0.7654 |
Loa Loa (eye worm) | indoleamine 2,3-dioxygenase | 0.1006 | 1 | 1 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0369 | 0.2065 | 0.1239 |
Brugia malayi | methionyl-tRNA synthetase | 0.0445 | 0.3014 | 0.2287 |
Echinococcus multilocularis | integrin beta 2 | 0.0602 | 0.4964 | 0.4411 |
Chlamydia trachomatis | methionine--tRNA ligase | 0.0382 | 0.2226 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.029 | 0.1075 | 0.1075 |
Echinococcus granulosus | integrin beta 2 | 0.0602 | 0.4964 | 0.4411 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0569 | 0.4559 | 0.4559 |
Entamoeba histolytica | methionyl-tRNA synthetase, putative | 0.0445 | 0.3014 | 0.5 |
Echinococcus granulosus | indoleamine 23 dioxygenase 2 | 0.1006 | 1 | 1 |
Echinococcus multilocularis | methionyl tRNA synthetase, cytoplasmic | 0.0382 | 0.2226 | 0.1372 |
Treponema pallidum | methionyl-tRNA synthetase | 0.0445 | 0.3014 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 10.9 nM | Binding affinity towards alpha V-beta3 receptor expressed in HEK293 cells | ChEMBL. | 15006384 |
IC50 (binding) | = 10.9 nM | Binding affinity towards alpha V-beta3 receptor expressed in HEK293 cells | ChEMBL. | 15006384 |
IC50 (binding) | = 21 nM | Binding affinity towards alpha V/beta3 receptor by solid-phase receptor binding assays (SPRA) | ChEMBL. | 15006384 |
IC50 (binding) | = 21 nM | Binding affinity towards alpha V/beta3 receptor by solid-phase receptor binding assays (SPRA) | ChEMBL. | 15006384 |
IC50 (binding) | = 93 nM | Binding affinity towards alpha IIb/beta3 integrin by solid-phase receptor binding assay (SPRA) | ChEMBL. | 15006384 |
IC50 (binding) | = 93 nM | Binding affinity towards alpha IIb/beta3 integrin by solid-phase receptor binding assay (SPRA) | ChEMBL. | 15006384 |
IC50 (binding) | = 135 nM | Binding affinity towards alpha V-beta5 receptor expressed in HEK293 cells | ChEMBL. | 15006384 |
IC50 (binding) | = 135 nM | Binding affinity towards alpha V-beta5 receptor expressed in HEK293 cells | ChEMBL. | 15006384 |
IC50 (binding) | = 758 nM | Binding affinity towards alpha V-beta1 receptor expressed in HEK293 cells | ChEMBL. | 15006384 |
IC50 (binding) | = 758 nM | Binding affinity towards alpha V-beta1 receptor expressed in HEK293 cells | ChEMBL. | 15006384 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.